Importance of gastrin in the pathogenesis and treament of gastric tumors

World Journal of Gastroenterology

Volumn 15, Issue 1, 2009, Pages 1-16

  Burkitt, Michael D ^a   Varro, Andrea ^a   Pritchard, D Mark ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Gastric carcinoma; Helicobacter pylori; Hypergastrinemia; Neuroendocrine; Proton pump inhibitor

Indexed keywords

CANCER VACCINE; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; CISPLATIN; FLUOROURACIL; FOLINIC ACID; G17DT VACCINE; GASTRIN; PROGLUMIDE; PROTON PUMP INHIBITOR; UNCLASSIFIED DRUG;

ACHLORHYDRIA; ANGIOGENESIS; APOPTOSIS; ATROPHIC GASTRITIS; CANCER GROWTH; CANCER SURGERY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; DRUG POTENTIATION; EDITORIAL; ENTEROCHROMAFFIN CELL; GASTRINOMA; GENETIC POLYMORPHISM; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HORMONE ACTION; HORMONE BLOOD LEVEL; HUMAN; HYPERGASTRINEMIA; LABORATORY TEST; MOUSE STRAIN; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NEUROENDOCRINE TUMOR; NONHUMAN; STOMACH ACID SECRETION; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH CARCINOGENESIS; STOMACH EPITHELIUM; STOMACH POLYP; TRANSGENIC MOUSE; ZOLLINGER ELLISON SYNDROME;

EID: 59249095362     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.1     Document Type: Editorial

References (120)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108
2. Edkins JS. The chemical mechanism of gastric secretion. J Physiol 1906; 34: 133-144
3. Dockray GJ, Varro A, Dimaline R, Wang T. The gastrins: their production and biological activities. Annu Rev Physiol 2001; 63: 119-139
4. Wang TC, Koh TJ, Varro A, Cahill RJ, Dangler CA, Fox JG, Dockray GJ. Processing and proliferative effects of human progastrin in transgenic mice. J Clin Invest 1996; 98: 1918-1929
5. Koh TJ, Dockray GJ, Varro A, Cahill RJ, Dangler CA, Fox JG, Wang TC. Overexpression of glycine-extended gastrin in transgenic mice results in increased colonic proliferation. J Clin Invest 1999; 103: 1119-1126
6. Buchan AM, Squires PE, Ring M, Meloche RM. Mechanism of action of the calcium-sensing receptor in human antral gastrin cells. Gastroenterology 2001; 120: 1128-1139
7. Schmitz F, Göke MN, Otte JM, Schrader H, Reimann B, Kruse ML, Siegel EG, Peters J, Herzig KH, Fölsch UR, Schmidt WE. Cellular expression of CCK-A and CCK-B/gastrin receptors in human gastric mucosa. Regul Pept 2001; 102: 101-110
8. Willems G, Vansteenkiste Y, Limbosch JM. Stimulating effect of gastrin on cell proliferation kinetics in canine fundic mucosa. Gastroenterology 1972; 62: 583-589
9. Kidd M, Tang LH, Modlin IM, Zhang T, Chin K, Holt PR, Moss SF. Gastrin-mediated alterations in gastric epithelial apoptosis and proliferation in a mastomys rodent model of gastric neoplasia. Digestion 2000; 62: 143-151
10. Hansen OH, Pedersen T, Larsen JK, Rehfeld JF. Effect of gastrin on gastric mucosal cell proliferation in man. Gut 1976; 17: 536-541
11. Bordi C, Cocconi G, Togni R, Vezzadini P, Missale G. Gastric endocrine cell proliferation. Association with Zollinger-Ellison syndrome. Arch Pathol 1974; 98: 274-278
12. Larsson H, Carlsson E, Mattsson H, Lundell L, Sundler F, Sundell G, Wallmark B, Watanabe T, Häkanson R. Plasma gastrin and gastric enterochromaffinlike cell activation and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology 1986; 90: 391-399
13. Lamberts R, Brunner G, Solcia E. Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa. Digestion 2001; 64: 205-213
14. Singh P, Indaram A, Greenberg R, Visvalingam V, Bank S. Long term omeprazole therapy for reflux esophagitis: follow-up in serum gastrin levels,EC cell hyperplasia and neoplasia. World J Gastroenterol 2000; 6: 789-792
15. Sun WH, Zhu F, Chen GS, Su H, Luo C, Zhao QS, Zhang Y, Shao Y, Sun J, Zhou SM, Ding GX, Cheng YL. Blockade of cholecystokinin-2 receptor and cyclooxygenase-2 synergistically induces cell apoptosis, and inhibits the proliferation of human gastric cancer cells in vitro. Cancer Lett 2008; 263: 302-311
16. Song DH, Rana B, Wolfe JR, Crimmins G, Choi C, Albanese C, Wang TC, Pestell RG, Wolfe MM. Gastrin-induced gastric adenocarcinoma growth is mediated through cyclin D1. Am J Physiol Gastrointest Liver Physiol 2003; 285: G217-G222
17. Varro A, Noble PJ, Wroblewski LE, Bishop L, Dockray GJ. Gastrin-cholecystokinin(B) receptor expression in AGS cells is associated with direct inhibition and indirect stimulation of cell proliferation via paracrine activation of the epidermal growth factor receptor. Gut 2002; 50: 827-833
18. Dickson JH, Grabowska A, El-Zaatari M, Atherton J, Watson SA. Helicobacter pylori can induce heparin-binding epidermal growth factor expression via gastrin and its receptor. Cancer Res 2006; 66: 7524-7531
19. Wang TC, Dangler CA, Chen D, Goldenring JR, Koh T, Raychowdhury R, Coffey RJ, Ito S, Varro A, Dockray GJ, Fox JG. Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology 2000; 118: 36-47
20. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767
21. Houghton J, Stoicov C, Nomura S, Rogers AB, Carlson J, Li H, Cai X, Fox JG, Goldenring JR, Wang TC. Gastric cancer originating from bone marrow-derived cells. Science 2004; 306: 1568-1571
22. Cui G, Takaishi S, Ai W, Betz KS, Florholmen J, Koh TJ, Houghton J, Pritchard DM, Wang TC. Gastrin-induced apoptosis contributes to carcinogenesis in the stomach. Lab Invest 2006; 86: 1037-1051
23. Przemeck SM, Varro A, Berry D, Steele I, Wang TC, Dockray GJ, Pritchard DM. Hypergastrinemia increases gastric epithelial susceptibility to apoptosis. Regul Pept 2008; 146: 147-156
24. Ramamoorthy S, Stepan V, Todisco A. Intracellular mechanisms mediating the anti-apoptotic action of gastrin. Biochem Biophys Res Commun 2004; 323: 44-48
25. Todisco A, Ramamoorthy S, Witham T, Pausawasdi N, Srinivasan S, Dickinson CJ, Askari FK, Krametter D. Molecular mechanisms for the antiapoptotic action of gastrin. Am J Physiol Gastrointest Liver Physiol 2001; 280: G298-G307
26. Pritchard DM, Berry D, Przemeck SM, Campbell F, Edwards SW, Varro A. Gastrin increases mcl-1 expression in type I gastric carcinoid tumors and a gastric epithelial cell line that expresses the CCK-2 receptor. Am J Physiol Gastrointest Liver Physiol 2008; 295: G798-G805
27. Chen CN, Hsieh FJ, Cheng YM, Chang KJ, Lee PH. Expression of inducible nitric oxide synthase and cyclooxygenase-2 in angiogenesis and clinical outcome of human gastric cancer. J Surg Oncol 2006; 94: 226-233
28. Subramaniam D, Ramalingam S, May R, Dieckgraefe BK, Berg DE, Pothoulakis C, Houchen CW, Wang TC, Anant S. Gastrin-mediated interleukin-8 and cyclooxygenase-2 gene expression: differential transcriptional and posttranscriptional mechanisms. Gastroenterology 2008; 134: 1070-1082
29. Konturek PC, Rembiasz K, Konturek SJ, Stachura J, Bielanski W, Galuschka K, Karcz D, Hahn EG. Gene expression of ornithine decarboxylase, cyclooxygenase-2, and gastrin in atrophic gastric mucosa infected with Helicobacter pylori before and after eradication therapy. Dig Dis Sci 2003; 48: 36-46
30. Clarke PA, Dickson JH, Harris JC, Grabowska A, Watson SA. Gastrin enhances the angiogenic potential of endothelial cells via modulation of heparin-binding epidermal-like growth factor. Cancer Res 2006; 66: 3504-3512
31. Wroblewski LE, Pritchard DM, Carter S, Varro A. Gastrinstimulated gastric epithelial cell invasion: the role and mechanism of increased matrix metalloproteinase 9 expression. Biochem J 2002; 365: 873-879
32. Varro A, Kenny S, Hemers E, McCaig C, Przemeck S, Wang TC, Bodger K, Pritchard DM. Increased gastric expression of MMP-7 in hypergastrinemia and significance for epithelial-mesenchymal signaling. Am J Physiol Gastrointest Liver Physiol 2007; 292: G1133-G1140
33. Noble PJ, Wilde G, White MR, Pennington SR, Dockray GJ, Varro A. Stimulation of gastrin-CCKB receptor promotes migration of gastric AGS cells via multiple paracrine pathways. Am J Physiol Gastrointest Liver Physiol 2003; 284: G75-G84
34. Wang TC, Bonner-Weir S, Oates PS, Chulak M, Simon B, Merlino GT, Schmidt EV, Brand SJ. Pancreatic gastrin stimulates islet differentiation of transforming growth factor alpha-induced ductular precursor cells. J Clin Invest 1993; 92: 1349-1356
35. Fox JG, Rogers AB, Ihrig M, Taylor NS, Whary MT, Dockray G, Varro A, Wang TC. Helicobacter pylori-associated gastric cancer in INS-GAS mice is gender specific. Cancer Res 2003; 63: 942-950
36. Takaishi S, Cui G, Frederick DM, Carlson JE, Houghton J, Varro A, Dockray GJ, Ge Z, Whary MT, Rogers AB, Fox JG, Wang TC. Synergistic inhibitory effects of gastrin and histamine receptor antagonists on Helicobacter-induced gastric cancer. Gastroenterology 2005; 128: 1965-1983
37. Cui G, Koh TJ, Chen D, Zhao CM, Takaishi S, Dockray GJ, Varro A, Rogers AB, Fox JG, Wang TC. Overexpression of glycine-extended gastrin inhibits parietal cell loss and atrophy in the mouse stomach. Cancer Res 2004; 64: 8160-8166
38. Koh TJ, Goldenring JR, Ito S, Mashimo H, Kopin AS, Varro A, Dockray GJ, Wang TC. Gastrin deficiency results in altered gastric differentiation and decreased colonic proliferation in mice. Gastroenterology 1997; 113: 1015-1025
39. Friis-Hansen L, Sundler F, Li Y, Gillespie PJ, Saunders TL, Greenson JK, Owyang C, Rehfeld JF, Samuelson LC. Impaired gastric acid secretion in gastrin-deficient mice. Am J Physiol 1998; 274: G561-G568
40. Nomura S, Yamaguchi H, Ogawa M, Wang TC, Lee JR, Goldenring JR. Alterations in gastric mucosal lineages induced by acute oxyntic atrophy in wild-type and gastrin-deficient mice. Am J Physiol Gastrointest Liver Physiol 2005; 288: G362-G375
41. Kirton CM, Wang T, Dockray GJ. Regulation of parietal cell migration by gastrin in the mouse. Am J Physiol Gastrointest Liver Physiol 2002; 283: G787-G793
42. Friis-Hansen L, Rieneck K, Nilsson HO, Wadström T, Rehfeld JF. Gastric inflammation, metaplasia, and tumor development in gastrin-deficient mice. Gastroenterology 2006; 131: 246-258
43. Sun FJ, Kaur S, Ziemer D, Banerjee S, Samuelson LC, De Lisle RC. Decreased gastric bacterial killing and upregulation of protective genes in small intestine in gastrin-deficient mouse. Dig Dis Sci 2003; 48: 976-985
44. Zavros Y, Rieder G, Ferguson A, Samuelson LC, Merchant JL. Genetic or chemical hypochlorhydria is associated with inflammation that modulates parietal and G-cell populations in mice. Gastroenterology 2002; 122: 119-133
45. Zavros Y, Eaton KA, Kang W, Rathinavelu S, Katukuri V, Kao JY, Samuelson LC, Merchant JL. Chronic gastritis in the hypochlorhydric gastrin-deficient mouse progresses to adenocarcinoma. Oncogene 2005; 24: 2354-2366
46. Wang X, Willén R, Wadström T, Aleljung P. RAPD-PCR, Histopathological and Serological Analysis of Four Mouse Strains Infected with Multiple Strains of Helicobacter pylori. Microb Ecol Health Dis 1999; 10: 148-154
47. Wang X, Willén R, Andersson C, Wadström T. Development of high-grade lymphoma in Helicobacter pylori-infected C57BL/ 6 mice. APMIS 2000; 108: 503-508
48. Zhao CM, Wang X, Friis-Hansen L, Waldum HL, Halgunset J, Wadström T, Chen D. Chronic Helicobacter pylori infection results in gastric hypoacidity and hypergastrinemia in wild-type mice but vagally induced hypersecretion in gastrin-deficient mice. Regul Pept 2003; 115: 161-170
49. Nagata A, Ito M, Iwata N, Kuno J, Takano H, Minowa O, Chihara K, Matsui T, Noda T. G protein-coupled cholecystokinin-B/gastrin receptors are responsible for physiological cell growth of the stomach mucosa in vivo. Proc Natl Acad Sci USA 1996; 93: 11825-11830
50. Langhans N, Rindi G, Chiu M, Rehfeld JF, Ardman B, Beinborn M, Kopin AS. Abnormal gastric histology and decreased acid production in cholecystokinin-B/gastrin receptor-deficient mice. Gastroenterology 1997; 112: 280-286
51. Rindi G, Langhans N, Rehfeld JF, Beinborn M, Kopin AS. Abnormal gastric morphology and function in CCK-B/gastrin receptor-deficient mice. Yale J Biol Med 1998; 71: 347-354
52. Chen D, Zhao CM, Al-Haider W, Håkanson R, Rehfeld JF, Kopin AS. Differentiation of gastric ECL cells is altered in CCK(2) receptor-deficient mice. Gastroenterology 2002; 123: 577-585
53. Jensen RT, Niederle B, Mitry E, Ramage JK, Steinmuller T, Lewington V, Scarpa A, Sundin A, Perren A, Gross D, O'Connor JM, Pauwels S, Kloppel G. Gastrinoma (duodenal and pancreatic). Neuroendocrinology 2006; 84: 173-182
54. Zollinger RM, Ellison EH. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg 1955; 142: 709-723; discussion, 724-728
55. Ito T, Tanaka M, Sasanc, H, Osamura YR, Sasaki I, Kimura W, Takano K, Obara T, Ishibashi M, Nakao K, Doi R, Shimatsu A, Nishida T, Komoto I, Hirata Y, Imamura M, Kawabe K, Nakamura K. Preliminary results of a Japanese nationwide survey of neuroendocrine gastrointestinal tumors. J Gastroenterol 2007; 42: 497-500
56. Piecha G, Chudek J, Wiecek A. Multiple Endocrine Neoplasia type 1. Eur J Intern Med 2008; 19: 99-103
57. Smith JT, Pounder RE, Nwokolo CU, Lanzon-Miller S, Evans DG, Graham DY, Evans DJ Jr. Inappropriate hypergastrinaemia in asymptomatic healthy subjects infected with Helicobacter pylori. Gut 1990; 31: 522-525
58. Levi S, Beardshall K, Swift I, Foulkes W, Playford R, Ghosh P, Calam J. Antral Helicobacter pylori, hypergastrinaemia, and duodenal ulcers: effect of eradicating the organism. BMJ 1989; 299: 1504-1505
59. Moss SF, Legon S, Bishop AE, Polak JM, Calam J. Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease. Lancet 1992; 340: 930-932
60. Carmel R. Prevalence of undiagnosed pernicious anemia in the elderly. Arch Intern Med 1996; 156: 1097-1100
61. Kogawa K. Parietal cell antibodies. Part II. Cytotoxic activities of parietal cell antibodies. Experiment 1. The observations on cytotoxic activities of parietal cell antibodies to normal human parietal cells in vitro. Experiment 2. The histochernical changes of rat stomach after administrations of rabbit anti-rat gastric mucosa sera. Gastroenterol Jpn 1975; 10: 52-64
62. Pritchard DM, Przemeck SM. Review article: How useful are the rodent animal models of gastric adenocarcinoma? Aliment Pharmacol Ther 2004; 19: 841-859
63. El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraumeni JF Jr, Rabkin CS. Interieukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404: 398-402
64. Presotto F, Sabini B, Cecchetto A, Plebani M, De Lazzari F, Pedini B, Betterle C. Helicobacter pylori infection and gastric autoimmune diseases: is there a link? Helicobacter 2003; 8: 578-584
65. Stolte M, Meier E, Meining A. Cure of autoimmune gastritis by Helicobacter pylori eradication in a 21-year-old male. Z Gastroenterol 1998; 36: 641-643
66. Havu N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion 1986; 35 Suppl 1: 42-55
67. Burkitt MD, Pritchard DM. Review article: Pathogenesis and management of gastric carcinoid tumours. Aliment Pharmacol Ther 2006; 24: 1305-1320
68. Berna MJ, Annibale B, Marignani M, Luong TV, Corleto V, Pace A, Ito T, Liewehr D, Venzon DJ, Delle Fave G, Bordi C, Jensen RT. A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors. J Clin Endocrinol Metab 2008, 93: 1582-1591
69. Carboni M, Guadagni S, Pistoia MA, Amicucci G, Lolli D, Palumbo G, Luclovico C, Walters C, Smith P, Viti G. Chronic atrophic gastritis and risk of N-nitroso compounds carcinogenesis. Langenbecks Arch Chir 1988; 373: 82-90
70. Jensen RT. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol 2006; 98: 4-19
71. Fujii T, Kawai T, Saito K, Hishima T, Hayashi Y, Imura J, Hironaka M, Hosoya Y, Koike M, Fukayama M. MEN1 gene mutations in sporadic neuroendocrine tumors of foregut derivation. Pathol Int 1999; 49: 968-973
72. D'Adda T, Keller G, Bordi C, Höfler H. Loss of heterozygosity in 11q13-14 regions in gastric neuroendocrine tumors not associated with multiple endocrine neoplasia type 1 syndrome. Lab Invest 1999; 79: 671-677
73. Higham AD, Dimaline R, Varro A, Attwood S, Armstrong G, Dockray GJ, Thompson DG. Octreotide suppression test predicts beneficial outcome from antrectomy in a patient with gastric carcinoid tumor. Gastroenterology 1998; 114: 817-822
74. Correa P. A human model of gastric carcinogenesis. Cancer Res 1988; 48: 3554-3560
75. McGuigan JE, Trudeau WL. Serum and tissue gastrin concentrations in patients with carcinoma of the stomach. Gastroenterology 1973; 64: 22-25
76. Rakic S, Milicevic M. Serum gastrin levels in patients with intestinal and diffuse type of gastric cancer. Br J Cancer 1991; 64: 1189
77. Soran A, Aslar AK, Cöl C. Are preoperative serum gastrin levels related to resertability and survival in gastric cancer? Int J Clin Pract 2000; 54: 652-653
78. Lin JT, Lee WC, Wu MS, Wang JT, Wang TH, Chen CJ. Diagnosis of gastric adenocarcinoma using a scoring system: combined assay of serological markers of Helicobacter pylori infection, pepsinogen I and gastrin. J Gastroenterol 1995; 30: 156-161
79. Storskrubb T, Aro P, Ronkainen J, Sipponen P, Nyhlin H, Talley NJ, Engstrand L, Stolte M, Vieth M, Walker M, Agréus L. Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: The Kalixanda study. Scand J Gastroenterol 2008; 43: 1448-1455
80. Hansen S, Vollset SE, Derakhshan MH, Fyfe V, Melby KK, Aase S, Jellum E, McColl KE. Two distinct aetiologies of cardia cancer; evidence from premorbid serological markers of gastric atrophy and Helicobacter pylori status. Gut 2007; 56: 918-925
81. Koivusalo AI, Pakarinen MP, Kolho KL. Is GastroPanel serum assay useful in the diagnosis of Helicobacter pylori infection and associated gastritis in children? Diagn Microbiol Infect Dis 2007; 57: 35-38
82. Henwood M, Clarke PA, Smith AM, Watson SA. Expression of gastrin in developing gastric adenocarcinoma. Br J Surg 2001; 88: 564-568
83. Hur K, Kwak MK, Lee HJ, Park DJ, Lee HK, Lee HS, Kim WH, Michaeli D, Yang HK. Expression of gastrin and its receptor in human gastric cancer tissues. J Cancer Res Clin Oncol 2006; 132: 85-91
84. Stephens MR, Hopper AN, Lewis WG, Blackshaw G, Edwards P, Osborne B, Thompson IW. Prognostic significance of gastrin expression in patients undergoing R0 gastrectomy for adenocarcinoma. Gastric Cancer 2007; 10: 159-166
85. Harrison JD, Jones JA, Morris DL. The effect of the gastrin receptor antagonist proglumide on survival in gastric carcinoma. Cancer 1990; 66: 1449-1452
86. Watson SA, Michaeli D, Grimes S, Morris TM, Robinson G, Varro A, Justin TA, Hardcastle JD. Gastrimmune raises antibodies that neutralize amidated and glycine-extended gastrin-17 and inhibit the growth of colon cancer. Cancer Res 1996; 56: 880-885
87. Watson SA, Morris TM, Varro A, Michaeli D, Smith AM. A comparison of the therapeutic effectiveness of gastrin neutralisation in two human gastric cancer models: relation to endocrine and autocrine/paracrine gastrin mediated growth. Gut 1999; 45: 812-817
88. Gilliam AD, Watson SA, Henwood M, McKenzie AJ, Humphreys JE, Elder J, Iftikhar SY, Welch N, Fielding J, Broome P, Michaeli D. A phase II study of G17DT in gastric carcinoma. Eur J Surg Oncol 2004; 30: 536-543
89. Ajani JA, Randolph Hecht J, Ho L, Baker J, Oortgiesen M, Eduljee A, Michaeli D. An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced-gastric or gastroesophageal cancer: the GC4 study. Cancer 2006; 106: 1908-1916
90. Konturek PC, Konturek SJ, Starzyska T, Marlicz K, Bielanski W, Pierzchalski P, Karczewska E, Hartwich A, Rembiasz K, Lawniczak M, Ziemniak W, Hahn EC. Helicobacter pylorigastrin link in MALT lymphoma. Aliment Pharmacol Ther 2000; 14: 1311-1318
91. Ohashi S, Segawa K, Okamura S, Urano F, Kanamori S, Hosoi T, Ishikawa H, Kanamori A, Kitabatake S, Sano H, Kobayashi T, Maeda M. Gastrin and Helicobacter pylori in low-grade MALT lymphoma patients. Scand J Gastroenterol 2002; 37: 279-286
92. Abraham SC, Nobukawa B, Giardiello FM, Hamilton SR, Wu TT. Sporadic fundic gland polyps: common gastric polyps arising through activating mutations in the beta-catenin gene. Am J Pathol 2001; 158: 1005-1010
93. Bianchi LK, Burke CA, Bennett AE, Lopez R, Hasson H, Church JM, Fundic gland polyp dysplasia is common in familial adenomatous polyposis. Clin Gastroenterol Hepatol 2008; 6: 180-185
94. Attard TM, Cuffari C, Tajouri T, Stoner JA, Eisenberg MT, Yardley JH, Abraham SC, Perry D, Vanderhoof J, Lynch H. Multicenter experience with upper gastrointestinal polyps in pediatric patients with familial adenomatous polyposis. Am J Gastroenterol 2004; 99: 681-686
95. Jalving M, Koornstra JJ, Götz JM, van der Waaij LA, de Jong S, Zwart N, Karrenbeld A, Kleibeuker JH. High-grade dysplasia in sporadic fundic gland polyps: a case report and review of the literature. Eur J Gastroenterol Hepatol 2003; 15: 1229-1233
96. Jalving M, Koornstra JJ, Boersma-van Ek W, de Jong S, Karrenbeld A, Hollema H, de Vries EG, Kleibeuker JH. Dysplasia in fundic gland polyps is associated with nuclear beta-catenin expression and relatively high cell turnover rates. Scand J Gastroenterol 2003; 38: 916-922
97. Abraham SC, Park SJ, Mugartegui L, Hamilton SR, Wu TT. Sporadic fundic gland polyps with epithelial dysplasia: evidence for preferential targeting for mutations in the adenomatous polyposis coli gene. Am J Pathol 2002; 161: 1735-1742
98. Kuipers EJ. Proton pump inhibitors and gastric neoplasia. Gut 2006; 55: 1217-1221
99. Possmark R, Jianu. CS, Martinsen TC, Qvigstad G, Syversen U, Waldum HL. Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition. Scand J Gastroenterol 2007; 1-5
100. Yeomans ND, Dent J. Personal review: alarmism or legitimate concerns about long-term suppression of gastric acid secretion? Aliment Pharmacol Ther 2000; 14: 267-271
101. Waldum HL, Brenna E. Personal review: is profound acid inhibition safe? Aliment Pharmacol Ther 2000; 14: 15-22
102. Coté GA, Howden CW. Potential adverse effects of proton pump inhibitors. Curr Gastroenterol Rep 2008; 10: 208-214
103. Lou HY, Chang CC, Sheu MT, Chen YC, Ho HO. Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism. Eur J Clin Pharmacol 2008
104. Klinkenberg-Knol EC, Nelis F, Dent J, Snel P, Mitchell B, Prichard P, Lloyd D, Havu N, Frame MH, Romàn J, Walan A. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118: 661-669
105. Hirschowitz BI, Worthington J, Mohnen J. Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2008; 27: 1110-1121
106. Ruscin JM, Page RL 2nd, Valuck RJ. Vitamin B(12) deficiency associated with histamine (2)-receptor antagonists and a proton-pump inhibitor. Ann Pharmacother 2002; 36: 812-816
107. Hutchinson C, Geissler CA, Powell JJ, Bomford A. Proton pump inhibitors suppress absorption of dietary nonhaem iron in hereditary haemochromatosis. Gut 2007; 56: 1291-1295
108. Kaur S, Vaishnavi C, Prasad KK, Ray P, Kochhar R. Comparative role of antibiotic and proton pump inhibitor in experimental Clostridium difficile infection in mice. Microbiol Immunol 2007; 51: 1209-1214
109. Jayatilaka S, Shakov R, Eddi R, Bakaj G, Baddoura WJ, DeBari VA. Clostridium difficile infection in an urban medical center: five-year analysis of infection rates among adult admissions and association with the use of proton pump inhibitors. Ann Clin Lab Sci 2007; 37: 241-247
110. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007; 102: 2047-2056; quiz 2057
111. O'Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 2005; 118: 778-781
112. Cui GL, Syversen U, Zhao CM, Chen D, Waldum HL. Long-term omeprazole treatment suppresses body weight gain and bone mineralization in young male rats. Scand J Gastroenterol 2001; 36: 1011-1015
113. Ottewell PD, Watson AJ, Wang TC, Varro A, Dockray GJ, Pritchard DM. Progastrin stimulates murine colonic epithelial mitosis after DNA damage. Gastroenterology 2003; 124: 1348-1357
114. Singh P, Velasco M, Given R, Varro A, Wang TC. Progastrin expression predisposes mice to colon carcinomas and adenomas in response to a chemical carcinogen. Gastroenterology 2000; 119: 162-171
115. Cobb S, Wood T, Tessarollo L, Velasco M, Given R, Varro A, Tarasova N, Singh P. Deletion of functional gastrin gene markedly increases colon carcinogenesis in response to azoxymethane in mice. Gastroenterology 2002; 123: 516-530
116. Rünkorg K, Veraksits A, Kurrikoff K, Luuk H, Raud S, Abramov U, Matsui T, Bourin M, Kõks S, Vasar E. Distinct changes in the behavioural effects of morphine and naloxone in CCK2 receptor-deficient mice. Behav Brain Res 2003; 144: 125-135
117. Abramov U, Raud S, Innos J, Kõks S, Matsui T, Vasar E. Gender specific effects of ethanol in mice, lacking CCK2 receptors. Behav Brain Res 2006; 175: 149-156
118. Rünkorg K, Veraksits A, Kurrikoff K, Luuk H, Raud S, Abramov U, Matsui T, Bourin M, Kõks S, Vasar E. Distinct changes in the behavioural effects of morphine and naloxone in CCK2 receptor-deficient mice. Behav Brain Res 2003; 144: 125-135
119. Abramov U, Raud S, Kõks S, Innos J, Kurrikoff K, Matsui T, Vasar E. Targeted mutation of CCK(2) receptor gene antagonises behavioural changes induced by social isolation in female, but not in male mice. Behav Brain Res 2004; 155: 1-11
120. Raud S, Innos J, Abramov U, Reimets A, Kõks S, Soosaar A, Matsui T, Vasar E. Targeted invalidation of CCK2 receptor gene induces anxiolytic-like action in light-dark exploration, but not in fear conditioning test. Psychopharmacology (Berl) 2005; 181: 347-357